Compare IDYA & CLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | CLBT |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | Israel |
| Employees | N/A | 1285 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 2019 | N/A |
| Metric | IDYA | CLBT |
|---|---|---|
| Price | $31.70 | $13.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $52.86 | $22.50 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $218,710,000.00 | N/A |
| Revenue This Year | N/A | $21.45 |
| Revenue Next Year | $201.05 | $17.47 |
| P/E Ratio | ★ N/A | $45.29 |
| Revenue Growth | ★ 3024.43 | N/A |
| 52 Week Low | $16.82 | $11.03 |
| 52 Week High | $39.28 | $20.53 |
| Indicator | IDYA | CLBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 49.41 |
| Support Level | $29.51 | $13.01 |
| Resistance Level | $34.76 | $15.09 |
| Average True Range (ATR) | 2.02 | 0.69 |
| MACD | 0.09 | 0.10 |
| Stochastic Oscillator | 19.44 | 60.85 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.